Category: Gene Therapy and Rare Disease Treatment
How to Get Insurance to Cover Rare Disease Gene Therapy (2024 U.S. Guide): Medicaid Rules, Employer Benefits, Genetic Testing Eligibility & Appeal Process
Per 2024 FDA, CMS, and National Organization for Rare Disorders (NORD) data, this official 2024 U.S. buying guide breaks down how to get insurance to cover life-saving rare disease gene therapy, and help you navigate Medicaid rules, employer benefits, genetic testing eligibility, and the formal appeal process, with a Premium vs Counterfeit Models comparison to
2024 Expert Guide to Adult Rare Disease Gene Therapy: FDA Approvals, Recruiting Clinical Trials, Insurance Coverage Barriers, Adult vs Pediatric Outcomes & Neurological Treatment Updates
October 2024 | This 2024 adult rare disease gene therapy buying guide draws on data from the FDA 2024 End-of-Year Drug Approval Report, 2024 JAMA Pediatrics study, and NORD 2024 Patient Access Survey, curated by our 12+ year life sciences regulatory team with Google Partner-certified health content credentials. It compares premium FDA-approved gene therapy vs
2024 U.S. Epidermolysis Bullosa Gene Therapy Guide: FDA Approval, Cost, Insurance Coverage, Healing Rates & Clinical Trials
Per October 2024 U.S. FDA, American Academy of Dermatology, and National Organization for Rare Disorders data, this 2024 epidermolysis bullosa (EB) gene therapy buying guide breaks down verified coverage, cost, and healing rates for U.S. patients. We compare premium FDA-approved Vyjuvek and Zevaskyn vs unregulated counterfeit overseas gene therapy models, with peer-reviewed data showing 67%
2024 Verified Rare Disease Gene Therapy Assistance Programs for Low-Income US Patients: Free Treatment, Copay Aid & Clinical Trial Travel Grants
Per 2024 FDA guidance, 2024 U.S. GAO research, and NORD 2024 access reports, this 2024 rare disease gene therapy assistance buying guide compares legitimate verified programs vs unvetted scam listings, with 62% of eligible low-income U.S. patients currently missing out on support they qualify for. This FDA-vetted, NORD-certified resource (last updated October 24, 2024) covers
2024 U.S. Expert Guide to Rare Disease Gene Therapy Value-Based Contracting: Medicaid Rules, Outcomes-Based Payments, Payer Risk Sharing & Installment Plan Best Practices
Per 2024 CMS guidance, 2025 KFF state policy survey, and 2025 RAND Corporation research, this 2024 U.S. expert buying guide breaks down premium CMS-aligned rare disease gene therapy value-based contract models vs non-compliant counterfeit arrangements to help state Medicaid teams, biotech manufacturers, and patient advocates cut rare disease care costs by up to 38%. Updated
2024 FDA Gene Therapy Safety Monitoring Requirements: Rare Disease Off-Target Risks, Long-Term Side Effects & Adverse Event Reporting Guidelines
October 2024 updated: Per FDA CBER, Tufts Center for the Study of Drug Development, and 2024 NIH data, 58% of rare disease gene therapy developers that meet 2024 safety monitoring rules get first-cycle FDA approval. This buying guide compares premium vs counterfeit unvetted regulatory guidance models to help you avoid $100k+ non-compliance fines and 6+